HEALTH● LOWSep 29 · Sep 29, 2026, 5:28 PM
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC
Seeking Alpha Tech · global
AstraZeneca has submitted a New Drug Application (NDA) for the combination of savolitinib and Tagrisso for the treatment of Non-Small Cell Lung Cancer (NSCLC). This represents a potential new therapeutic option for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH53m agoThe health of Leo XIV: the Pope advances in his recovery, but uncertainty remains about his visit to South AmericaClarínHEALTH1h agoHealthcare workers protest in virtually every state over pay, shortages and staffingMexico News DailyHEALTH2h agoKFF: Individual health insurance enrollment fell 18 percent in JuneThe HillHEALTH2h agoPaxton suing Gerber and Nestlé over alleged arsenic and lead in baby foodThe Hill